Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 279 participants.
Also called NCT06987695
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 279 participants
- Sponsor
- Registry
-
NCT06987695
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Japan
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06987695. Randomized; double masking; primary purpose treatment. Start 2025-06-13 (actual); primary completion 2027-04-27 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
- Acronym
- MARITIME-3-J
- Condition
- Obesity Disease
- Intervention (Drug)
- Maridebart cafraglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct06987695- Content hash
d084faad060f4aeb08457122f169f4d080f7cb506a54a13397e456640a3d3091